Cancer Patient Guide

Breast Cancer: Expert Insights for Treatment Decisions

Curated from expert webinars (part of 150+ across all cancer types) hosted by Cancer Patient Lab, a 501(c)(3) nonprofit. Covers HER2, triple-negative, hormone receptor positive, BRCA mutations, Oncotype DX, and the latest in immunotherapy and targeted therapy.

Expert Panel

Oncologists and researchers who contributed insights through Cancer Patient Lab webinars

Catalina Lopez-Correa, MD, PhD

Genomics and precision medicine in breast cancer

Sandra Balladares, PhD

Breast cancer research and treatment advances

Tony Letai, MD, PhD

Functional precision medicine — testing drugs on cancer cells

Lisa Butterfield

Cancer vaccines and immunotherapy

Ezra Cohen, MD

AI tools in cancer patient-doctor conversations

Lauren Leiman

Liquid biopsy for cancer monitoring

Treatment Topics

Key treatment areas covered across our breast cancer webinar series

HER2-Targeted Therapy

HER2-positive breast cancer has seen transformative advances with antibody-drug conjugates like T-DXd (Enhertu), which has also shown efficacy in HER2-low tumors. Understanding your HER2 status — positive, low, or negative — now directly impacts which targeted therapies you may be eligible for, including combinations with immunotherapy.

Triple-Negative Breast Cancer (TNBC)

TNBC lacks hormone receptors and HER2, making it harder to target. However, immunotherapy with checkpoint inhibitors (pembrolizumab) combined with chemotherapy has become standard for many TNBC patients. BRCA-mutated TNBC may also respond to PARP inhibitors like olaparib, and antibody-drug conjugates like sacituzumab govitecan offer new options after initial treatment.

Hormone Receptor-Positive Breast Cancer

The most common subtype, HR+ breast cancer is driven by estrogen and/or progesterone receptors. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy have dramatically improved outcomes. Oncotype DX and MammaPrint genomic tests help determine whether chemotherapy adds benefit beyond hormone therapy alone.

BRCA Mutations & Genetic Testing

BRCA1 and BRCA2 mutations significantly increase breast cancer risk and affect treatment choices. PARP inhibitors (olaparib, talazoparib) are FDA-approved for BRCA-mutated breast cancer. Genetic testing can also inform family screening and risk-reduction strategies including prophylactic surgery and enhanced monitoring.

Genomic Testing & Treatment Planning

Oncotype DX, MammaPrint, and comprehensive genomic profiling (FoundationOne CDx, Tempus) help personalize treatment. These tests can identify whether chemotherapy will benefit you, reveal actionable mutations, and guide clinical trial eligibility. Dr. Tony Letai's functional precision medicine approach tests drugs directly on cancer cells to predict response.

Common Questions from Breast Cancer Patients

Answered by Navis AI, informed by expert webinars and medical guidelines

Testing Services for Breast Cancer

Genomic testing, liquid biopsy, and molecular profiling services relevant to breast cancer

Browse all 369 services →

Breast Cancer Webinars

From Cancer Patient Lab — a 501(c)(3) nonprofit

Get Personalized Breast Cancer Insights

Upload your pathology report, genomic test, or lab results. Our AI translates them into plain English and matches you to relevant services and clinical trials.

This page is for informational purposes only and does not constitute medical advice. Content is curated from expert webinars hosted by Cancer Patient Lab, a 501(c)(3) nonprofit. Always consult your oncologist for treatment decisions. Meet our team →